SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Promising Antitumor Activity in Epithelial Ovarian Carcinoma with HER2/Neu Expression

BACKGROUND: Epithelial ovarian cancer (EOC) is an aggressive and heterogeneous disease. Less than 10% of EOC demonstrate HER2/neu 3+ receptor over-expression. However, moderate to low (ie, 2+ and 1+) HER2/neu expression is reported in up to 50% of EOC. The objective of this study was to compare the...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Gynecol Oncol
Autores principales: Menderes, Gulden, Bonazzoli, Elena, Bellone, Stefania, Black, Jonathan, Altwerger, Gary, Masserdotti, Alice, Pettinella, Francesca, Zammataro, Luca, Buza, Natalia, Hui, Pei, Wong, Serena, Litkouhi, Babak, Ratner, Elena, Silasi, Dan-Arin, Huang, Gloria S, Azodi, Masoud, Schwartz, Peter E., Santin, Alessandro D.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2017
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5533304/
https://ncbi.nlm.nih.gov/pubmed/28473206
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2017.04.023
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares